Cipher Pharmaceuticals (CPH) Stock Overview
Operates as a specialty pharmaceutical company in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CPH from our risk checks.
CPH Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Cipher Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$19.13 |
| 52 Week High | CA$19.59 |
| 52 Week Low | CA$10.61 |
| Beta | 0.52 |
| 1 Month Change | 26.19% |
| 3 Month Change | 30.22% |
| 1 Year Change | 64.49% |
| 3 Year Change | 479.70% |
| 5 Year Change | 1,317.04% |
| Change since IPO | 417.03% |
Recent News & Updates
Recent updates
Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Nov 09
These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Oct 10Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
Aug 29We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
May 16Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
May 09Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Apr 28
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Dec 13Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Nov 14With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Nov 12Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Nov 09There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Mar 23Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
Mar 22Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock
May 14Shareholder Returns
| CPH | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 4.3% | 18.0% | 3.7% |
| 1Y | 64.5% | 58.1% | 44.2% |
Return vs Industry: CPH exceeded the Canadian Pharmaceuticals industry which returned 50.8% over the past year.
Return vs Market: CPH exceeded the Canadian Market which returned 41.4% over the past year.
Price Volatility
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 19.3% |
| 10% least volatile stocks in CA Market | 3.8% |
Stable Share Price: CPH has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CPH's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients. The company’s licensed products comprise Absorica, an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Conzip, an opioid agonist for the management of moderate to moderately severe chronic pain in adults; and Lipofen, an adjunctive therapy to diet to reduce elevated LDL-C, total-C, triglycerides, and Apo B, as well as to increase HDL-C.
Cipher Pharmaceuticals Inc. Fundamentals Summary
| CPH fundamental statistics | |
|---|---|
| Market cap | CA$475.78m |
| Earnings (TTM) | CA$38.03m |
| Revenue (TTM) | CA$70.21m |
Is CPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPH income statement (TTM) | |
|---|---|
| Revenue | US$50.45m |
| Cost of Revenue | US$10.03m |
| Gross Profit | US$40.42m |
| Other Expenses | US$13.09m |
| Earnings | US$27.33m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.08 |
| Gross Margin | 80.12% |
| Net Profit Margin | 54.17% |
| Debt/Equity Ratio | 4.0% |
How did CPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/06 11:18 |
| End of Day Share Price | 2026/04/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cipher Pharmaceuticals Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |